Market Research Logo

Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H2 2015

Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H2 2015’, provides an overview of the Transitional Cell Cancer (Urothelial Cell Cancer)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Transitional Cell Cancer (Urothelial Cell Cancer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Transitional Cell Cancer (Urothelial Cell Cancer) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Transitional Cell Cancer (Urothelial Cell Cancer)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Transitional Cell Cancer (Urothelial Cell Cancer) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Transitional Cell Cancer (Urothelial Cell Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Transitional Cell Cancer (Urothelial Cell Cancer) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Transitional Cell Cancer (Urothelial Cell Cancer)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Transitional Cell Cancer (Urothelial Cell Cancer) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Transitional Cell Cancer (Urothelial Cell Cancer) Overview
Therapeutics Development
Pipeline Products for Transitional Cell Cancer (Urothelial Cell Cancer) - Overview
Pipeline Products for Transitional Cell Cancer (Urothelial Cell Cancer) - Comparative Analysis
Transitional Cell Cancer (Urothelial Cell Cancer) - Therapeutics under Development by Companies
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Transitional Cell Cancer (Urothelial Cell Cancer) - Products under Development by Companies
Transitional Cell Cancer (Urothelial Cell Cancer) - Companies Involved in Therapeutics Development
Altor BioScience Corporation
Amgen Inc.
Astellas Pharma Inc.
AstraZeneca Plc
ATLAB Pharma SAS
Bayer AG
BIND Therapeutics, Inc.
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Celgene Corporation
Corcept Therapeutics Incorporated
Eisai Co., Ltd.
Eli Lilly and Company
Exelixis, Inc.
Incyte Corporation
Innate Immunotherapeutics Limited
Johnson & Johnson
Merck & Co., Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
Mirati Therapeutics Inc.
Novartis AG
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
PsiOxus Therapeutics Limited
Sanofi
Sumitomo Dainippon Pharma Co., Ltd.
Teva Pharmaceutical Industries Limited
Transitional Cell Cancer (Urothelial Cell Cancer) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ACP-196 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AdIL-24 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
afatinib dimaleate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALT-801 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMG-228 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
amrubicin hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASG-15ME - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ATL-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
avelumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AZD-4547 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
B-701 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BBI-503 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
buparlisib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cabazitaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cabozantinib s-malate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CEP-11981 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
docetaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
enadenotucirev - Drug Profile
Product Description
Mechanism of Action
R&D Progress
enfortumab vedotin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
epacadostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
eribulin mesylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
everolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
gedatolisib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
icrucumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INCB-54828 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ixazomib citrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
JNJ-42756493 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lenalidomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lenvatinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mifepristone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MIS-416 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mitomycin SR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mocetinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nintedanib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nivolumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
palbociclib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pembrolizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ramucirumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
regorafenib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAR-408701 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sunitinib malate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
trametinib dimethyl sulfoxide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vandetanib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Transitional Cell Cancer (Urothelial Cell Cancer) - Recent Pipeline Updates
Transitional Cell Cancer (Urothelial Cell Cancer) - Dormant Projects
Transitional Cell Cancer (Urothelial Cell Cancer) - Discontinued Products
Transitional Cell Cancer (Urothelial Cell Cancer) - Product Development Milestones
Featured News & Press Releases
May 30, 2015: Mirati Therapeutics Provided Updates on Mocetinostat at 2015 ASCO Annual Meeting
May 13, 2015: Mirati Therapeutics to Provide Updates on Mocetinostat at 2015 ASCO Annual Meeting
May 07, 2013: Exelixis To Feature Nine Presentations On Cabozantinib At 2013 ASCO Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Transitional Cell Cancer (Urothelial Cell Cancer), H2 2015
Number of Products under Development for Transitional Cell Cancer (Urothelial Cell Cancer) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Development by Companies, H2 2015 (Contd..3)
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Altor BioScience Corporation, H2 2015
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Amgen Inc., H2 2015
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Astellas Pharma Inc., H2 2015
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by AstraZeneca Plc, H2 2015
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by ATLAB Pharma SAS, H2 2015
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Bayer AG, H2 2015
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by BIND Therapeutics, Inc., H2 2015
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Boehringer Ingelheim GmbH, H2 2015
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Boston Biomedical, Inc., H2 2015
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Celgene Corporation, H2 2015
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Corcept Therapeutics Incorporated, H2 2015
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Eisai Co., Ltd., H2 2015
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Eli Lilly and Company, H2 2015
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Exelixis, Inc., H2 2015
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Incyte Corporation, H2 2015
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Innate Immunotherapeutics Limited, H2 2015
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Johnson & Johnson, H2 2015
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Merck & Co., Inc., H2 2015
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Merck KGaA, H2 2015
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Mirati Therapeutics Inc., H2 2015
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Novartis AG, H2 2015
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Pfizer Inc., H2 2015
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by PsiOxus Therapeutics Limited, H2 2015
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Sanofi, H2 2015
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2015
Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics - Recent Pipeline Updates, H2 2015
Transitional Cell Cancer (Urothelial Cell Cancer) - Dormant Projects, H2 2015
Transitional Cell Cancer (Urothelial Cell Cancer) - Dormant Projects (Contd..1), H2 2015
Transitional Cell Cancer (Urothelial Cell Cancer) - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Transitional Cell Cancer (Urothelial Cell Cancer), H2 2015
Number of Products under Development for Transitional Cell Cancer (Urothelial Cell Cancer) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report